Systemic JIA — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Start an interleukin-1 or interleukin-6 inhibitor early in treatment
Current Still-disease strategy introduces IL-1 or IL-6 inhibition early, using glucocorticoid only as a short bridge when necessary and aiming for clinically inactive disease off glucocorticoid. Methotrexate may help a residual articular phenotype but is not the preferred first controller of prominent systemic disease.
Reference: NICE TA685: anakinra for Still disease (Published March 2021): https://www.nice.org.uk/guidance/ta685/chapter/1-Recommendations; EULAR/PReS recommendations for Still disease across children and adults (Published November 2024): https://ard.bmj.com/content/83/12/1614